AstraZeneca PLC - American Depositary Shares (AZN)

As of today, December 22, 2025, Pfizer Inc. (NYSE: PFE) stands as a case study in corporate reinvention and the brutal reality of the post-pandemic "hangover." Once the darling of the global healthcare sector during the peak of the COVID-19 crisis, the pharmaceutical giant is currently navigating one of the most challenging chapters in its [...]

AstraZeneca (AZN) shows a top technical rating and a high-quality consolidation pattern, signaling a potential breakout opportunity for technical traders.

The deals expand the pricing program to most targeted drugmakers in exchange for temporary tariff relief.

The stocks listed here trade at forward earnings multiples of less than 18.

The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing.

The New Year is shaping up to be an important one for this quantum computing stock.

The report states that the agreement between the U.S. and the U.K. is expected to be announced in the coming days.

Pricing updates for major therapies from Novo Nordisk, Teva, AbbVie, and others eased sector worries.

Novo Nordisk stock jumped Wednesday on a lighter-than-feared discount for Ozempic and Wegovy under the IRA.

AstraZeneca (AZN) is a top-quality stock for long-term investors, showing strong revenue growth, high profitability, and solid cash flow generation.

The company is wasting little time figuring out the particulars of a sweeping capital investment program.

AstraZeneca receives FDA approval for Koselugo to treat adults with NF1 and inoperable plexiform neurofibromas, backed by strong Phase 3 data.

A lot can happen for this quantum computing leader over the next decade.

Johnson & Johnson said Monday it's putting up $3.05 billion to buy privately held cancer player Halda Therapeutics.

November 14, 2025 – Quantum computing pioneer IonQ (NYSE: IONQ) recently captured significant market attention, with its stock experiencing a notable 3.6% gain on November 5, 2025, driven by an impressive upward revision of its revenue forecasts. This positive momentum was further underscored by a key insider purchase just days

The company inches closer to bringing a new drug to a very large addressable market.

The artificial intelligence (AI) sector is currently navigating a period of unprecedented dynamism, characterized by explosive technological advancements, massive capital inflows, and a palpable tension between investor optimism and concerns over valuation. As of November 2025, the AI market stands at a pivotal juncture, with a concentrated surge in mega-cap AI players driving overall market [...]

AstraZeneca's Baxdrostat cut blood pressure by 14 mmHg in the Phase 3 Bax24 trial, showing strong efficacy and safety in resistant hypertension patients.

This quantum computing pioneer has tremendous potential.

The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results that are validating extensive research and development efforts across the industry. Investors are demonstrating a renewed appetite for risk,

Fueled by gains in all of its therapeutic areas, the company had a triumphant third quarter.

The Trump administration struck deals with Eli Lilly and Novo Nordisk to lower obesity drug prices and expand Medicare coverage starting in 2026.

AstraZeneca's Q3 sales rose 12% to $15.19 billion, beating forecasts as cancer and biopharma growth lifted results; 2025 guidance reaffirmed.

After a brief and cautious rebound on Wednesday, risk-off sentiment returned sharply on Thursday, with AI-linked stocks leading a broad selloff across Wall Street and renewed pressure hitting crypto markets.